314.34MMarket Cap-1694P/E (TTM)
1.298High1.220Low1.28MVolume1.230Open1.230Pre Close1.61MTurnover0.75%Turnover RatioLossP/E (Static)255.56MShares2.05052wk High12.95P/B209.55MFloat Cap0.42052wk Low--Dividend TTM170.37MShs Float21.570Historical High--Div YieldTTM6.32%Amplitude0.420Historical Low1.258Avg Price1Lot Size
Adaptimmune Therapeutics Stock Forum
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
No comment yet